The Arctic Group is a leading, independent provider of financial services
We are looking for an ambitious, enthusiastic, and dedicated team member to join our High Yield Sales team in Stockholm. The salesperson shall cover private investors, family offices and high net individuals, and is expected to already have an existing client portfolio. Arctic Securities’ High Yield Sales team consists of experienced employees highly recognized both locally and by international institutions.
Arctic Securities acted sole manager in relation to the private placement of SEK 55m for the electric motorcycle company RGNT Electric AB. The capitalizations aim is to scale manufacturing and deliver on demand. We are grateful for the vote of confidence and congratulate on the successful transaction!
On Tuesday (April 13) the US Center for Disease Control (CDC) and Food and Drug Administration (FDA) announced recommended a pause in the use of Johnson & Johnson’s COVID-19 vaccine following six cases of a severe brain blot clots known as cerebral venous sinus thrombosis (CVST) in combination with low levels of blood platelets (a type of white blood cell). While this adverse event is rare, as close to 7 million doses of the vaccine has been administered to date, it is severe and carrier a high risk of mortality. EU countries were about to initiate distribution of the vaccine, but those efforts have now also been put on hold.
Arctic Securities is acting as financial advisor in relation to the use of warrants of series TO4 in ExpreS2ion Biotech Holding AB (publ). ExpreS2ion Biotech Holding AB (publ) is referred to as “ExpreS2ion” or “the Company”. Three (3) warrant of series TO4 entitles the holder to subscribe for one (1) new share in ExpreS2ion at a subscription price of SEK 22.00 during the period from April 12 – April 26, 2021. The terms and conditions are presented in the prospectus, which is available on ExpreS2ion’s website, www.expres2ionbio.com and Arctic Securities website together with a subscription note.
